BACKGROUND

According to international transgender care guidelines, an important prerequisite for puberty suppression (PS) is transgender adolescents’ competence to give informed consent (IC). In society, there is doubt whether transgender adolescents are capable of this, which in some countries has even led to limited access to this intervention. Therefore, this study examined transgender adolescents’ medical decision-making competence (MDC) to give IC for starting PS in a structured, replicable way. Additionally, potential associated variables on MDC, such as age, intelligence, sex, psychological functioning, were investigated.

METHODS

A cross-sectional semistructured interview study with 74 transgender adolescents (aged 10–18 years; 16 birth-assigned boys, 58 birth-assigned girls) within two Dutch specialized gender-identity clinics was performed. To assess MDC, judgements based on the reference standard (clinical assessment) and the MacArthur Competence Assessment Tool for Treatment (MacCAT-T), a validated semistructured interview, were used.

RESULTS

Of the transgender adolescents, 93.2% (reference standard judgements; 69 of 74) and 89.2% (MacCAT-T judgements; 66 of 74) were assessed competent to consent. Intermethod agreement was 87.8% (65 of 74). Interrater agreements of the reference standard and MacCAT-T-based judgements were 89.2% (198 of 222) and 86.5% (192 of 222), respectively. IQ and sex were both significantly related to MacCAT-T total score, whereas age, level of emotional and behavioral challenges, and diagnostic trajectories duration were not.

CONCLUSIONS

By using the MacCAT-T and clinicians’ assessments, 93.2% and 89.2%, respectively, of the transgender adolescents in this study were assessed competent to consent for starting PS.

What’s Known on This Subject:

According to international transgender care guidelines, an important prerequisite for puberty suppression is transgender adolescents’ competence to give informed consent (IC). However, some doubt adolescents’ ability to provide valid IC because of their age and potential consequences of this decision.

What This Study Adds:

This study presents empirical outcomes of assessment of transgender adolescents’ medical decision-making competence (MDC) to give IC for starting puberty suppression. In addition, potential associated variables on MDC, such as age, intelligence, sex, and psychological functioning, are presented.

In December 2020, the High Court of Justice in London ruled that, in the United Kingdom, transgender minors aged ≤15 years are highly unlikely to fully understand the long-term effect of puberty suppression (PS) (gonadotropin-releasing hormone agonist) and to give informed consent (IC).1  Other countries and states have considered or applied similar age-based restrictions in access to this care as well.2  However, evidence regarding transgender minors’ medical decision-making competence (MDC) was lacking until now. To our knowledge, the current study is the first to present empirical outcomes of assessment of transgender minors’ MDC.

Transgender people have a feeling of discrepancy between their birth-assigned sex and gender identity.3  In this article, the term “(birth-assigned) sex” is used for an anatomic or chromosomal determination, as opposed to gender, which refers to an internal sense of self as man, woman, another gender or no gender. When puberty starts, transgender minors have to deal with body changes they abhor. In the 1990s, the Dutch introduced treatment with PS, which allows transgender adolescents to further mature and accrue life experience before decisions are made regarding successive gender-affirming treatment with permanent physical changes.46 

In the Netherlands, transgender adolescents undergo a diagnostic trajectory, including a psycho-diagnostic assessment and several monthly sessions with a mental health provider over a longer period of time (usually ∼6 months), when assessing eligibility for PS. PS at early stages of puberty improves psychological functioning and ameliorates general functioning, and physical outcome may be better.79  As far as currently known, the effects of this treatment are fully reversible when discontinued.6  However, there are worries about the impact of PS on physical, cognitive, and psychosocial development and the capability of making decisions about this treatment with profound implications (eg, regarding fertility) at this young age.911  Minors’ MDC for interventions is a major issue in pediatric ethics. Therefore, according to the international guidelines, one of the criteria for transgender adolescents to start PS is having sufficient mental capacity to give IC.6,12  Of note, gonadotropin-releasing hormone agonists are standard of care for treatment in children with precocious puberty.13 

Minors are a protected population and, in most circumstances, not accorded the legal right to consent. Local jurisdictions determine age limits for minors’ alleged MDC, which vary widely between countries.14,15  Research reveals that minors who have not yet reached the legally set age for MDC often have the mental capacity to understand the implications of a decision.16  In contrast, minors may differ from adults by not yet having developed stable long-term goals in life and basing their decisions on values that might change.17  Additionally, minors are not as likely as adults to consider the benefits and risks associated with a decision.18  In our study, to deal with discrepancies between local laws and international jurisdictions, we focused on adolescents’ decision-making competence or capacity for giving consent regarding the decision to start treatment with PS, regardless of the legal age to give IC (alone or together with their parents). In the context of our study, legally, parents have to give consent when the child is aged <12 years; between the ages of 12 and 15 years, parents and child both have to give consent; and at age ≥16 years, the child is allowed to give consent independently.

MDC describes the capacities needed for making an autonomous medical decision.19  To reach MDC, a person needs to fulfill 4 criteria: (1) understand the information relevant to one’s condition and the proposed treatment; (2) appreciate the nature of one’s circumstances, including one’s current medical situation and the underlying values; (3) reason about benefits and potential risks of the options; and (4) be able to express a choice.20  MDC is relative to a specific task and context. It is 1 of the 3 prerequisites for giving a valid IC, next to being well-informed and without coercion.21,22 

In pediatric daily practice, MDC is generally assessed implicitly and in an unstructured way, which may lead to inconsistencies.23  A study in which researchers reviewed 23 existing measures reveals that the MacArthur Competence Assessment Tool for Treatment (MacCAT-T) has the most empirical support for assessing MDC.19,2426  The MacCAT-T proved reliable in assessing mental competence in adult patients with dementia, schizophrenia, and other psychiatric conditions.2729 

The cognitive, emotional, and social abilities of minors develop over time and so do their decision-making capacities.15  Age is often considered to be the best determinant for assessing MDC.30  Some research reveals that 12 years is a common age to reach MDC.31  Other research reveals that minors <12 years of age may be capable of making well-considered decisions and that minors from the age of 9 years are capable of understanding the issues involved in clinical trials.32,33  Contributing factors for MDC are intelligence and psychological functioning.30,34  People with limited cognitive capacities may have more difficulty understanding information.34  Research suggests that psychiatric conditions and psychopathology might impair MDC.2729 

Little research exists regarding minors’ MDC.35  Specifically, there is no empirical evidence on transgender adolescents’ MDC to decide on PS. In clinical practice and policy making, age standards prescribed by law may have too much influence on the clinicians’ assessments.35  In addition, clinicians’ assessments of MDC are influenced by their personal subjective views of what is in the adolescent’s best interest.36  The right balance needs to be struck between respecting transgender adolescents’ autonomy and protecting adolescents who are not fully capable of making these decisions themselves.23 

To fill the gaps in knowledge regarding transgender adolescents’ MDC, in this cross-sectional semistructured interview study, we aimed to answer the following questions:

  1. Are transgender adolescents com- petent to give IC for starting PS, according to the standard IC procedure and the MacCAT-T?

  2. What is the intermethod agree- ment between MDC judgements based on the standard IC procedure and the MacCAT-T?

  3. What is the interrater agreement regarding MDC judgements between raters using the standard IC procedure and the MacCAT-T?

  4. To what extent are age, intelligence, psychological functioning, duration of the diagnostic trajectory, sex, and family situation associated with transgender adolescents’ MDC for starting PS?

Participants were transgender adolescents visiting the Center of Expertise on Gender Dysphoria of the Amsterdam University Medical Centers, Location VUmc in Amsterdam, the Netherlands, between January 1, 2016, and December 31, 2017, or visiting the gender-identity clinic of Leiden University Medical Center, Leiden University Medical Center Curium, in Leiden, the Netherlands, between March 1, 2017, and December 31, 2017. The researchers identified the adolescents who were about to start PS through the medical files, and the adolescents and their parents were invited by the involved clinician to participate. The study protocol was approved by the institutional review boards of the participating institutions. Written information was provided, and signed IC for participation was obtained from all participants and their parents.

All adolescents visiting the clinics were eligible for study participation; there was no selection process. Not speaking Dutch and being cisgender were exclusion criteria. In this study, no distinction was made in describing the gender identity of the participants other than being transgender. The adolescents who participated in the study were, as recommended by the Standards of Care, at least at Tanner stage 2.12  The clinics’ protocols use PS until age 17 years to prepare for more definite affirming treatment by hormones and, in some individual cases, >17 years when creating rest and time for further gender-identity exploration are indicated. Seventy-four adolescents participated, whereas 206 eligible adolescents were not reached or did not want to or could not participate (Fig 1). There were no significant differences between the participating and nonparticipating adolescents with regard to demographics (Table 1).

FIGURE 1

Flowchart of Adolescent Participation.

FIGURE 1

Flowchart of Adolescent Participation.

Close modal
TABLE 1

Comparison of Characteristics of Participating and Nonparticipating Adolescents MacCAT-T

VariablesParticipating AdolescentsNonparticipating AdolescentsP
Age, y   .09 
N 73a 206  
 Mean 14.71 15.18  
 Range 10.63–18.34 10.10–18.36  
Total IQ   .65 
N 70b 195c  
 Mean 100.21 99.17  
 Range 66–144 61–144  
Assigned sex, n (%)   .39 
 Birth-assigned female 58 (78.4) 151 (73.3)  
 Birth-assigned male 16 (21.6) 55 (26.7)  
CBCL total-problem T score   .25 
N 57d 183e  
 Mean 60.42 58.78  
 Range 42–77 34–80  
Duration of diagnostic trajectory, mo   .43 
N 73a 206  
 Mean 9.55 10.29  
 Range 4–26 3–59  
Family situation, n (%)   .16 
 With both parents 39 (52.7) 128 (62.1)  
 Other 35 (47.3) 78 (37.9)  
VariablesParticipating AdolescentsNonparticipating AdolescentsP
Age, y   .09 
N 73a 206  
 Mean 14.71 15.18  
 Range 10.63–18.34 10.10–18.36  
Total IQ   .65 
N 70b 195c  
 Mean 100.21 99.17  
 Range 66–144 61–144  
Assigned sex, n (%)   .39 
 Birth-assigned female 58 (78.4) 151 (73.3)  
 Birth-assigned male 16 (21.6) 55 (26.7)  
CBCL total-problem T score   .25 
N 57d 183e  
 Mean 60.42 58.78  
 Range 42–77 34–80  
Duration of diagnostic trajectory, mo   .43 
N 73a 206  
 Mean 9.55 10.29  
 Range 4–26 3–59  
Family situation, n (%)   .16 
 With both parents 39 (52.7) 128 (62.1)  
 Other 35 (47.3) 78 (37.9)  

Age refers to age at the IC session; total IQ refers to full-scale IQ; CBCL refers to Child Behavior Checklist.

a

Date of starting with puberty-suppressing treatment was unknown for one participating adolescent.

b

Total IQ was missing for four participating adolescents.

c

Total IQ was missing for 11 nonparticipating adolescents.

d

CBCL total-problem T score was missing for 17 participating adolescents.

e

CBCL total-problem T score was missing for 23 nonparticipating adolescents.

Demographics

Adolescents’ demographic characteristics obtained from the medical files were date of birth, sex, family situation, date of the first contact at the clinic, and date of the IC session. Family situation was categorized into (1) living with both parents and (2) other.

Medical Decision-Making Competence

The MacCAT-T is a quantitative, semistructured interview used to assess the 4 MDC criteria and takes 15 to 20 minutes.19,20  In this study, the Dutch version modified for children and adolescents was used.35  In the current study, the disclosure of information was adapted to treatment with PS in transgender adolescents.15,19,35  Examples of interview-questions are “what would be possible consequences if you would choose to undergo this intervention, and what if you would not?” The tool provides a total score and subscale scores for each of the 4 MDC criteria. An overall cutoff score for MDC is not provided. The assessor weighs the subscale scores, along with contextual information (eg, substantial risks of treatment, far-reaching consequences, and whether there is support of caregivers), and judges MDC in each individual case. Recent research revealed that the 4 MDC criteria constitute a continuum or single trait in children.16 

Full-Scale Intelligence

Full-scale IQ was assessed by the Dutch Wechsler Intelligence Scale for Children in adolescents aged ≤16 years and by the Dutch Wechsler Adult Intelligence Scale in adolescents aged >16 years.37,38 

Child Behavior Checklist

The parent-reported Child Behavior Checklist (CBCL) was used to assess behavioral and emotional difficulties.39,40  The total-problem T score was calculated as age-standardized measure of total behavioral and emotional difficulties.

Both gender-identity clinics that participate in the study follow the Standards of Care and the Endocrine Society clinical practice guidelines.6,12  The diagnostic trajectory, which is spread over a longer period of time, concludes with a session for signing a printed IC statement by adolescents and parents. This standard IC session was videotaped and used to establish the reference standard for MDC in this study (see below), similar to previous studies.16,35  After the IC session, the MacCAT-T interview was administered by one of the researchers, which was also videotaped, to provide the MacCAT-T–based judgements of MDC.

A panel of 12 experts (including child psychiatrists, pediatric endocrinologists, child psychologists, and master thesis medical students) was trained in judging MDC on the basis of the 4 criteria, which are currently considered the generally accepted reference standard.16,24,41,42 

Of each IC video, 3 MDC judgements were performed: 2 by experts and 1 by the clinician involved in the diagnostic trajectory. These judgements were used for establishing the reference standard.

Each MacCAT-T video was also judged by 3 different experts, who rated the subscale scores, total score, and their MDC judgement. These assessments were used for the MacCAT-T–based judgements. The experts received the videos in random order, blinded to other judgements or adolescents’ characteristics.

All statistical analyses were performed by using SPSS, version 26 (IBM SPSS Statistics, IBM Corporation).43  Both for the reference standard and MacCAT-T–based judgements, MDC was considered present when at least 2 out of 3 judgements were positive.35 

The proportion of adolescents assessed positive on MDC was described as a raw percentage. The correlation between the reference standard and MacCAT-T–based judgements, as a measure of intermethod agreement, was also described as a raw percentage. Interrater agreement of the 3 reference standard and 3 MacCAT-T–based judgements, which is the overall percentage of mean fractions of agreement between the 3 raters, were calculated as raw percentages.

To discern potential associations between MacCAT-T total-scale scores and our main variables of interest (age, intelligence, CBCL total-problem T score, and duration of the diagnostic trajectory), demographic characteristics were identified as relevant control variables (eg, gender, family situation, and clinic location) as a first step. Second, multiple linear regression was used to identify variables correlated to the MacCAT-T total scores with pairwise deletion of missing variables.

Participants’ baseline characteristics are listed in Table 2.

TABLE 2

Descriptive Statistics for Characteristics of the Participants

VariablesBirth-Assigned BoysBirth-Assigned GirlsTotalP
Age, y    .15 
n 16 58 74  
 Mean 14.02 14.87 14.69  
 Range 12.02–17.11 10.63–18.34 10.63–18.34  
Total IQ    .82 
n 15 55 70a  
 Mean 99.47 100.42 100.21  
 Range 82–131 66–144 66–144  
CBCL total-problem T score    .91 
n 13 48 61b  
 Mean 60.62 60.94 60.87  
 Range 44–72 42–77 42–77  
 Percentage in clinical range, %c 38.5 43.7 42.6 .73 
Duration of diagnostic trajectory, mo    .64 
n 16 58 74  
 Mean 9.25 8.69 8.81  
 Range 4–18 2–26 2–26  
Family situation, n (%)    .71 
 With both parents 8 (50.0) 32 (55.2) 40 (54,1)  
 Other 8 (50.0) 26 (44.8) 34 (45.9)  
VariablesBirth-Assigned BoysBirth-Assigned GirlsTotalP
Age, y    .15 
n 16 58 74  
 Mean 14.02 14.87 14.69  
 Range 12.02–17.11 10.63–18.34 10.63–18.34  
Total IQ    .82 
n 15 55 70a  
 Mean 99.47 100.42 100.21  
 Range 82–131 66–144 66–144  
CBCL total-problem T score    .91 
n 13 48 61b  
 Mean 60.62 60.94 60.87  
 Range 44–72 42–77 42–77  
 Percentage in clinical range, %c 38.5 43.7 42.6 .73 
Duration of diagnostic trajectory, mo    .64 
n 16 58 74  
 Mean 9.25 8.69 8.81  
 Range 4–18 2–26 2–26  
Family situation, n (%)    .71 
 With both parents 8 (50.0) 32 (55.2) 40 (54,1)  
 Other 8 (50.0) 26 (44.8) 34 (45.9)  

Age refers to age at the IC session; total IQ refers to full-scale IQ; CBCL refers to Child Behavior Checklist.

a

Total IQ was missing for four participants.

b

CBCL total-problem T score was missing for 13 participants.

c

Clinical range: t ≥ 64 (Achenbach, 20011 ).

After the reference standard and MacCAT-T–based judgements, respectively, 93.2% (69 of 74) and 89.2% (66 of 74) of the adolescents were positive on MDC for starting PS. Table 3 shows characteristics of participants who were judged not competent.

TABLE 3

Characteristics of Participants Judged Not Competent by Using the Reference Standard and/or MacCAT-T

ParticipantAssigned SexReference StandardMacCAT-TAge, yTotal IQDuration of Diagnostic Trajectory, mo
Female Incompetent Incompetent 12 69 
Male Incompetent Incompetent 12 84 10 
Female Competent Incompetent 11 93 15 
Male Competent Incompetent 13 Missing 
Male Competent Incompetent 12 96 12 
Female Competent Incompetent 12 79 
Female Competent Incompetent 17 66 10 
Female Competent Incompetent 11 79 10 
Female Incompetent Competent 11 Missing 
10 Male Incompetent Competent 12 101 
11 Female Incompetent Competent 10 110 13 
ParticipantAssigned SexReference StandardMacCAT-TAge, yTotal IQDuration of Diagnostic Trajectory, mo
Female Incompetent Incompetent 12 69 
Male Incompetent Incompetent 12 84 10 
Female Competent Incompetent 11 93 15 
Male Competent Incompetent 13 Missing 
Male Competent Incompetent 12 96 12 
Female Competent Incompetent 12 79 
Female Competent Incompetent 17 66 10 
Female Competent Incompetent 11 79 10 
Female Incompetent Competent 11 Missing 
10 Male Incompetent Competent 12 101 
11 Female Incompetent Competent 10 110 13 

Age refers to age at the IC session; total IQ refers to full-scale IQ.

The reference standard and MacCAT-T–based judgements correlated in 87.8% (65 of 74) of the cases (see Table 4).

TABLE 4

Percentage of Competent and Incompetent According to the Reference Standard–Based Judgements and the MacCAT-T–Based Judgements of Transgender Adolescents’ MDC

Reference Standard (n = 74)MacCAT-T (n = 74)
CompetentIncompetentTotal
 Competent 85.1% (63) 8.1% (6) 69 
 Incompetent 4.1% (3) 2.7% (2) 
 Total 66 74 
Reference Standard (n = 74)MacCAT-T (n = 74)
CompetentIncompetentTotal
 Competent 85.1% (63) 8.1% (6) 69 
 Incompetent 4.1% (3) 2.7% (2) 
 Total 66 74 

The interrater agreement of the reference standard and MacCAT-T–based judgements for the 3 experts were 89.2% (198 of 222) and 86.5% (192 of 222), respectively.

Sex was significantly associated with MacCAT-T score (t[72] = −3.045; P = .003); birth-assigned girls showed a higher total score. Both family status and clinic location were not significantly associated with MacCAT-T score. Therefore, a multiple linear regression analysis was conducted with only sex as control variable and age, intelligence, psychological functioning, and duration of the diagnostic trajectory as the main variables of interest, with the MacCAT-T score as the dependent variable. Table 5 shows the results of the multiple linear regression analysis. A significant regression equation was found (F(5,52) = 3.685; P = .006). Sex and full-scale intelligence are both significantly related to the MacCAT-T score when each one was corrected for the other 3 variables (respectively, β = 3.636; t(52) = 2.685; P = .010; and β = 0.088; t(52) = 2.381; P = .02). Age at the IC session, CBCL total-problem T score and duration of the diagnostic trajectory were not significantly correlated.

TABLE 5

Multiple Linear Regression Analysis Comparing the Effect of Age, Full-Scale Intelligence, Psychological Functioning, Duration of the Diagnostic Trajectory Associated, and Sex to the MacCAT-T Score

BP95% Confidence Interval for B
Lower BoundUpper Bound
Step 1     
 Constant 29.177 — 24.211 34.142 
 Assigned sex 3.636 .01* 0.923 6.348 
Step 2     
 Constant 18.560 — 4.977 32.143 
 Age 0.476 .08 −0.056 1.008 
 Total IQ 0.088 .02* 0.014 0.161 
 CBCL total-problem T score −0.080 .19 −0.201 0.040 
 Duration of diagnostic trajectory 0.056 .67 −0.210 0.322 
BP95% Confidence Interval for B
Lower BoundUpper Bound
Step 1     
 Constant 29.177 — 24.211 34.142 
 Assigned sex 3.636 .01* 0.923 6.348 
Step 2     
 Constant 18.560 — 4.977 32.143 
 Age 0.476 .08 −0.056 1.008 
 Total IQ 0.088 .02* 0.014 0.161 
 CBCL total-problem T score −0.080 .19 −0.201 0.040 
 Duration of diagnostic trajectory 0.056 .67 −0.210 0.322 

Age refers to age at the IC session; total IQ refers to full-scale IQ; CBCL refers to Child Behavior Checklist; —, not applicable.

*

P value <.05.

The current study revealed that 93.2% and 89.2% of the transgender adolescents who were about to start PS and were participating in this study were competent to give IC on the basis of the standard clinical assessment and when using the MacCAT-T interview, respectively. This is a reassuring finding, which reveals that guidelines that require understanding the pros and cons of the treatment and capacity for IC for starting PS are followed for these participants.6,12  This study was performed after several sessions with adolescents and parents aimed at obtaining understanding of the consequences of PS, including not only the short-term, with regard to suppression of further feminization or virilization, but also long-term considerations of bone development, surgical options, and fertility.44 

This study further looked into several variables potentially associated with MDC. Of the examined variables, higher intelligence and sex (birth-assigned girls) were associated with higher MacCAT-T scores. The association of a higher intelligence with MDC is in line with other research.45,46  The birth-assigned girls in our study might have had a more advanced puberty compared with the birth-assigned boys, which might be related to a deeper understanding of the consequences of PS.47  Contrary to our expectations and earlier research, age was not correlated to MacCAT-T scores in this study. Although the participants seem like a representative sample, it may be too homogeneous, with regard to age, to detect a significant effect because the sample included few participants aged ≤11 years. Most research suggests that MDC is reached little before the age of 12 years.16,32,33  Finally, no association between duration of the diagnostic trajectory or behavioral and emotional difficulties was found. This finding was also against our expectation because psychological difficulties can interfere with MDC. However, one of the criteria for starting PS applied at the Dutch gender-identity clinics is “having no interfering psychosocial difficulties.”6,12  Therefore, by protocol, adolescents with severe psychosocial difficulties might have been referred for appropriate treatment before deciding on PS.

The results of this study confirm the feasibility of the Dutch version of the MacCAT-T for children and adolescents in assessing transgender adolescents’ MDC; the interrater agreement of the reference standard and MacCAT-T–based judgements were both high (respectively, 89.2% and 86.5%). Furthermore, the results of this study offer first indications of validity of the MacCAT-T for judging transgender adolescents’ MDC (intermethod agreement was 87.8%), and the MacCAT-T could therefore be used in clinical practice when MDC assessment is difficult. The MacCAT-T should not necessarily replace (a part of) the usual implicit assessment of MDC. However, in individual cases of doubt on MDC, the MacCAT-T could be used as a structured tool to underpin MDC assessment more objectively. Therefore, the tool will not be a barrier for access to care but can be used for due diligence. In the MacCAT-T, contextual information is weighted in the assessment, which may include parental support. It is expected that these results will be generalizable to other clinics because findings are in line with other research on the use of the MacCAT-T in youth (eg, in a population deciding on predictive genetic testing, in youth with HIV infection, and in a sample of adolescents with psychiatric conditions).35,48,49  Findings regarding the age for established MDC are congruent.

Although the study results reveal that most adolescents are considered competent to give IC for starting PS, nevertheless 6.8% to 10.8% are not, respectively, reference standard–based and MacCAT-T based. In all of these 11 adolescents assessed incompetent, except for one, the involved clinician had no doubts about the MDC. Possibly, the more positive judgement by these clinicians may be explained by their judgement on the basis of several sessions and not on a single assessment. In the one adolescent that was assessed incompetent by the involved clinician, the clinician added that she considered the adolescent’s mother competent to give (proxy) consent. So, in cases in which there is doubt regarding adolescents' MDC, clinicians may more heavily depend on the parents’ IC.50  Subsequently, time on PS could more explicitly be used to prepare MDC for treatment with lasting effects of gender-affirming hormones.

This is in line with statements in a recent qualitative study that the best interest for an individual should be taken into account when deciding whether to start PS.51  Other research reveals also that MDC assessment is regularly influenced by the clinicians’ ideas of what is in the child’s best interest.36  This might mean that some clinicians start PS in transgender adolescents who are assessed incompetent to consent on the basis of the principle of best interest.

In addition, the results of the current study do not answer questions on how to respect the developing autonomy of incompetent adolescents ethically. In the aforementioned qualitative interview study, some clinicians stated that transgender minors should at least partially depend on their parents to make decisions regarding PS.51  It could be that the parents’ role and responsibility should be more pronounced when an adolescent is deemed incompetent to consent.50 

Of note, the focus of this study was not on the putative association between MDC and having no regrets later in life about the decision to start PS. Competent transgender adolescents who begin PS may still potentially have regrets about the decision.

There are strengths and limitations to the current study. The study’s standardized nature provided a reproducible and interrater-reliable method for assessing MDC in transgender adolescents who were about to start PS. Nevertheless, because of the study’s design to only include adolescents who were about to start PS after a diagnostic trajectory, the sample contained relatively few adolescents aged <12 years, with low intelligence, showing serious (interfering) psychiatric conditions or psychopathology, and relatively few birth-assigned boys. Additionally, adolescent’s Tanner stage was not investigated in this study as a potential associated variable on MDC. Furthermore, on the basis of the current results, one cannot conclude with certainty whether the exploration and explanation during the diagnostic trajectory is essential in helping the transgender adolescents becoming competent to consent to PS or that MDC was already reached before the diagnostic trajectory.

In future work, researchers should especially focus on transgender adolescents aged <12 years starting this treatment, particularly birth-assigned girls who may benefit from PS as early as 9 years of age. Additional research is needed for adolescents with lower intelligence, serious developmental conditions, or psychopathology, for birth-assigned boys, and participants in early stages of puberty. More research is needed regarding the question what to do when an adolescent is incompetent to consent to the treatment; for example, what are the parents’ and the involved clinician’s role and responsibility in such a situation? In addition, qualitative research focused on the role of MDC in clinical practice and the principle of best interest are encouraged.

It is reassuring that the majority of the transgender adolescents participating in this study seem to have thoroughly thought about PS, understand what PS involves, and are deemed competent to decide. However, this might not be similar for all other contexts, particularly because our study cohort had extensive and thorough diagnostic evaluation before the MDC assessment as opposed to adolescents without this support. Additionally, the study results indicate feasibility and validity of the MacCAT-T in clinical practice. Nevertheless, as long as there are only limited data on transgender adolescents’ MDC for starting PS, an individualized approach is highly important for this group.

We thank the adolescents who have participated in this study. Furthermore, we would like to thank Dr Daniel Klink, Dr Corine van Diest, Dr Floor Haven, Dr Rodney van der Linde, Dr Wieteke Elzinga, Dr Jasmijn Oliemans, Dr Stijn Pasveer, Frederique Lichtenbeld, and the other experts of the panel who administered the MacCAT-T and standard IC sessions. We thank the clinicians who were willing to collaborate in recording the standard IC session. Additionally, we would like to thank the Alliantie Fonds of Amsterdam Public Health for funding the research project.

FUNDING: Funded by Alliantie Fonds of Amsterdam Public Health. The funding source had no role in the study design, in the writing of the manuscript, and in the decision to submit the manuscript for publication.

COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2021-053451.

Dr A. de Vries and Dr I. Hein conceptualized and designed the study, conducted the initial analyses, and critically reviewed and revised the manuscript; Dr M. de Vries conceptualized and designed the study and critically reviewed and revised the manuscript; Dr A. van der Miesen conducted the initial analyses and critically reviewed and revised the manuscript; Dr L. Vrouenraets collected data, conducted the initial analyses, and drafted the initial manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

CBCL

Child Behavior Checklist

IC

informed consent

MacCAT-T

MacArthur Competence Assessment Tool for Treatment

MDC

medical decision-making competence

PS

puberty suppression

1
Dyer
C
.
Puberty blockers: children under 16 should not be referred without court order, says NHS England
.
BMJ
.
2020
;
371
:
m4717
2
Walch
A
,
Davidge-Pitts
C
,
Safer
JD
,
Lopez
X
,
Tangpricha
V
,
Iwamoto
SJ
.
Proper care of transgender and gender diverse persons in the setting of proposed discrimination: a policy perspective
.
J Clin Endocrinol Metab
.
2021
;
106
(
2
):
305
308
3
World Health Organization
.
ICD-11 for mortality and morbidity statistics: gender incongruence
.
4
Cohen-Kettenis
PT
,
Steensma
TD
,
de Vries
ALC
.
Treatment of adolescents with gender dysphoria in the Netherlands
.
Child Adolesc Psychiatr Clin N Am
.
2011
;
20
(
4
):
689
700
5
Delemarre-van de Waal
HA
,
Cohen-Kettenis
PT
.
Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects
.
Eur J Endocrinol
.
2006
;
155
(
suppl_1
):
131
137
6
Hembree
WC
,
Cohen-Kettenis
PT
,
Gooren
L
, et al
.
Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline
.
J Clin Endocrinol Metab
.
2017
;
102
(
11
):
3869
3903
7
de Vries
ALC
,
Steensma
TD
,
Doreleijers
TAH
,
Cohen-Kettenis
PT
.
Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study
.
J Sex Med
.
2011
;
8
(
8
):
2276
2283
8
van der Miesen
AIR
,
Steensma
TD
,
de Vries
ALC
,
Bos
H
,
Popma
A
.
Psychological functioning in transgender adolescents before and after gender affirmative care compared to cisgender general population peers
.
J Adolesc Health
.
2020
;
66
(
6
):
699
704
9
Anacker
C
,
Sydnor
E
,
Chen
BK
, et al
.
Behavioral and neurobiological effects of GnRH agonist treatment in mice-potential implications for puberty suppression in transgender individuals
.
Neuropsychopharmacology
.
2021
;
46
(
5
):
882
890
10
Chen
D
,
Strang
JF
,
Kolbuck
VD
, et al
.
Consensus parameter: research methodologies to evaluate neurodevelopmental effects of pubertal suppression in transgender youth
.
Transgend Health
.
2020
;
5
(
4
):
246
257
11
Kreukels
BPC
,
Cohen-Kettenis
PT
.
Puberty suppression in gender identity disorder: the Amsterdam experience
.
Nat Rev Endocrinol
.
2011
;
7
(
8
):
466
472
12
Coleman
E
,
Bockting
WO
,
Botzer
M
, et al
.
Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7
.
Int J Transgenderism
.
2012
;
13
:
165
232
13
Carel
JC
,
Eugster
EA
,
Rogol
A
, et al;
ESPE-LWPES GnRH Analogs Consensus Conference Group
.
Consensus statement on the use of gonadotropin-releasing hormone analogs in children
.
Pediatrics
.
2009
.
14
Stultiëns
L
,
Goffin
T
,
Borry
P
,
Dierickx
K
,
Nys
H
.
Minors and informed consent: a comparative approach
.
Eur J Health Law
.
2007
;
14
(
1
):
21
46
15
Hein
IM
,
Troost
PW
,
Lindeboom
R
,
de Vries
MC
,
Zwaan
CM
,
Lindauer
RJ
.
Assessing children’s competence to consent in research by a standardized tool: a validity study
.
BMC Pediatr
.
2012
;
12
:
156
163
16
Hein
IM
,
Troost
PW
,
Lindeboom
R
, et al
.
Accuracy of the MacArthur competence assessment tool for clinical research (MacCAT-CR) for measuring children’s competence to consent to clinical research
.
JAMA Pediatr
.
2014
;
168
(
12
):
1147
1153
17
Cohen
P
,
Cohen
J
.
Life Values and Adolescents Mental Health
.
New York, NY
:
Psychology Press
;
1996
18
Halpern-Felsher
BL
,
Cauffman
E
.
Costs and benefits of a decision: decision-making competence in adolescents and adults
.
J Appl Dev Psychol
.
2001
;
22
:
257
273
19
Grisso
T
,
Appelbaum
PS
,
Hill-Fotouhi
C
.
The MacCAT-T: a clinical tool to assess patients’ capacities to make treatment decisions
.
Psychiatr Serv
.
1997
;
48
(
11
):
1415
1419
20
Appelbaum
PS
,
Grisso
T
.
Assessing patients’ capacities to consent to treatment
.
N Engl J Med
.
1988
;
319
(
25
):
1635
1638
21
Grisso
T
,
Appelbaum
PS
.
Comparison of standards for assessing patients’ capacities to make treatment decisions
.
Am J Psychiatry
.
1995
;
152
(
7
):
1033
1037
22
Beauchamp
TL
,
Childress
JF
.
Principles of Biomedical Ethics
.
New York, NY
:
Oxford University Press
;
2008
23
Appelbaum
PS
.
Clinical practice. Assessment of patients’ competence to consent to treatment
.
N Engl J Med
.
2007
;
357
(
18
):
1834
1840
24
Kim
SY
,
Caine
ED
,
Currier
GW
,
Leibovici
A
,
Ryan
JM
.
Assessing the competence of persons with Alzheimer’s disease in providing informed consent for participation in research
.
Am J Psychiatry
.
2001
;
158
(
5
):
712
717
25
Dunn
LB
,
Nowrangi
MA
,
Palmer
BW
,
Jeste
DV
,
Saks
ER
.
Assessing decisional capacity for clinical research or treatment: a review of instruments
.
Am J Psychiatry
.
2006
;
163
(
8
):
1323
1334
26
Kim
SY
,
Appelbaum
PS
,
Swan
J
, et al
.
Determining when impairment constitutes incapacity for informed consent in schizophrenia research
.
Br J Psychiatry
.
2007
;
191
:
38
43
27
Cairns
R
,
Maddock
C
,
Buchanan
A
, et al
.
Reliability of mental capacity assessments in psychiatric in-patients
.
Br J Psychiatry
.
2005
;
187
:
372
378
28
Owen
GS
,
Richardson
G
,
David
AS
,
Szmukler
G
,
Hayward
P
,
Hotopf
M
.
Mental capacity to make decisions on treatment in people admitted to psychiatric hospitals: cross sectional study
.
BMJ
.
2008
;
337
:
a448
29
Palmer
BW
,
Dunn
LB
,
Appelbaum
PS
, et al
.
Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument
.
Arch Gen Psychiatry
.
2005
;
62
(
7
):
726
733
30
Dorn
LD
,
Susman
EJ
,
Fletcher
JC
.
Informed consent in children and adolescents: age, maturation and psychological state
.
J Adolesc Health
.
1995
;
16
(
3
):
185
190
31
Billick
SB
,
Burgert
W
 III
,
Friberg
G
,
Downer
AV
,
Bruni-Solhkhah
SM
.
A clinical study of competency to consent to treatment in pediatrics
.
J Am Acad Psychiatry Law
.
2001
;
29
(
3
):
298
302
32
Billick
SB
,
Edwards
JL
,
Burgert
W
 III
,
Serlen
JR
,
Bruni
SM
.
A clinical study of competency in child psychiatric inpatients
.
J Am Acad Psychiatry Law
.
1998
;
26
(
4
):
587
594
33
Mårtenson
EK
,
Fägerskiöld
AM
.
A review of children’s decision-making competence in health care
.
J Clin Nurs
.
2008
;
17
(
23
):
3131
3141
34
Grisso
T
,
Appelbaum
PS
.
Assessing Competence to Consent to Treatment: A Guide for Physicians and Other Health Professionals
.
New York, NY
:
Oxford University Press
;
1998
35
Hein
IM
,
Troost
PW
,
Lindeboom
R
, et al
.
Feasibility of an assessment tool for children’s competence to consent to predictive genetic testing: a pilot study
.
J Genet Couns
.
2015
;
24
(
6
):
971
977
36
de Vries
MC
,
Wit
JM
,
Engberts
DP
,
Kaspers
GJ
,
van Leeuwen
E
.
Pediatric oncologists’ attitudes towards involving adolescents in decision-making concerning research participation
.
Pediatr Blood Cancer
.
2010
;
55
(
1
):
123
128
37
Wechsler
D
.
Wechsler Intelligence Scale for Children - Third Edition - Dutch Adaptation (WISC-III-NL)
.
Amsterdam
:
Pearson
;
2005
38
Wechsler
D
.
Wechsler Adult Intelligence Scale, Third Edition, Dutch version (WAIS-III-NL)
.
Lisse, Netherlands
:
Swets and Zetlinger
;
1997
39
Achenbach
TM
,
Rescorla
LA
.
Manual for the ASEBA School-Age Forms & Profiles: An Integrated System of Multi-informant Assessment
.
Burlington, VT
:
University of Vermont, Research Center for Children, Youth, & Families
;
2001
40
Verhulst
FC
,
van der Ende
J
.
ASEBA Manual. Questionnaires for the ages 6 to 18 years
.
Rotterdam
:
ASEBA Netherlands
;
2013
41
Etchells
E
,
Darzins
P
,
Silberfeld
M
, et al
.
Assessment of patient capacity to consent to treatment
.
J Gen Intern Med
.
1999
;
14
(
1
):
27
34
42
Carney
MT
,
Neugroschl
J
,
Morrison
RS
,
Marin
D
,
Siu
AL
.
The development and piloting of a capacity assessment tool
.
J Clin Ethics
.
2001
;
12
(
1
):
17
23
43
IBM Corp
.
IBM SPSS Statistics for Windows. Version 26.0
.
Armonk, NY
:
IBM Corp
;
2019
44
Di Ceglie
D
.
Autonomy and decision-making in children and adolescents with gender dysphoria
. In:
Shaw
M
,
Bailey
S
, eds.
Justice for Children and Families - A Developmental Perspective
.
Cambridge, UK
:
Cambridge University Press
;
2018
:
145
153
45
Hein
IM
,
Troost
PW
,
Lindeboom
R
, et al
.
Key factors in children’s competence to consent to clinical research
.
BMC Med Ethics
.
2015
;
16
(
1
):
74
46
Miller
VA
,
Drotar
D
,
Kodish
E
.
Children’s competence for assent and consent: a review of empirical findings
.
Ethics Behav
.
2004
;
14
(
3
):
255
295
47
Koerselman
K
,
Pekkarinen
T
.
The Timing of Puberty and Gender Differences in Educational Achievement. IZA Discussion Papers 10889
.
Bonn, Germany
:
IZA Institute of Labor Economics
;
2017
48
Chenneville
T
,
Machacek
M
,
Tan
R
,
Lujan-Zilberman
J
,
Emmanuel
P
,
Rodriguez
C
.
Decisional capacity among youth with HIV: results from the MacArthur Competence Tool for Treatment
.
AIDS Patient Care STDS
.
2014
;
28
(
8
):
425
432
49
Mandarelli
G
,
Sabatello
U
,
Lapponi
E
,
Pace
G
,
Ferrara
M
,
Ferracuti
S
.
Treatment decision-making capacity in children and adolescents hospitalized for an acute mental disorder: the role of cognitive functioning and psychiatric symptoms
.
J Child Adolesc Psychopharmacol
.
2017
;
27
(
5
):
462
465
50
Giordano
S
,
Garland
F
,
Holm
S
.
Gender dysphoria in adolescents: can adolescents or parents give valid consent to puberty blockers [published online ahead of print March 10, 2021]?
J Med Ethics
.
doi:10.1136/medethics-2020-106999
51
Vrouenraets
LJJJ
,
Fredriks
AM
,
Hannema
SE
,
Cohen-Kettenis
PT
,
de Vries
MC
.
Early medical treatment of children and adolescents with gender dysphoria: An empirical ethical study
.
J Adolesc Health
.
2015
;
57
(
4
):
367
373

Competing Interests

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.